Headline News

 

Lilly’s Taltz plus Zepbound highlights superior efficacy for adults with psoriatic arthritis and obesity

Posted on March 30, 2026

Dupixent approved as the first targeted medicine to treat adults with bullous pemphigoid in Japan

Posted on March 30, 2026

Sanofi’s Sarclisa subcutaneous formulation recommended for approval to treat multiple myeloma

Posted on March 30, 2026

Sanofi releases new results from amlitelimab phase 3 studies in atopic dermatitis

Posted on March 30, 2026

ICOTYDE receives approval for first in line systemic treatment of plaque psoriasis with a targeted oral peptide

Posted on March 24, 2026

Gilead to acquire Ouro Medicines to advance T cell engager program for autoimmune diseases

Posted on March 24, 2026

Bristol Myers Squibb transforms lymphoma treatment paradigm with expanded approvals for Opdivo

Posted on March 24, 2026

GSK’s Lynavoy approved for cholestatic pruritus in patients with primary biliary cholangitis

Posted on March 24, 2026

GSK’sri svutatug rezetecan granted Orphan Drug Designation for small-cell lung cancer in Japan

Posted on March 24, 2026

Retatrutide demonstrated reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

Posted on March 24, 2026

Pfizer and Valneva new lyme disease vaccine candidate emphasises strong efficacy in phase 3 VALOR trial

Posted on March 24, 2026

Pfizer releases new topline phase 2 results for CDK4 inhibitor, Atirmociclib in 2nd line Metastatic Breast Cancer

Posted on March 24, 2026

Dupixent approved as the first targeted medicine to treat adults with bullous pemphigoid in Japan

Posted on March 24, 2026

Sanofi’s venglustat receives breakthrough therapy designation for type 3 Gaucher disease in the U.S.

Posted on March 24, 2026

AbbVie releases new positive topline results from phase 1 multiple ascending dose study of ABBV-295

Posted on March 16, 2026